Quick Answer
OptimizeRx Corp reported Diluted EPS of $0.27 per share for fiscal year 2025.
OptimizeRx Corp Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $0.27 | +124.5% |
| 2024 | -$1.10 | -6.8% |
| 2023 | -$1.03 | -60.9% |
| 2022 | -$0.64 | -3300.0% |
| 2021 | $0.02 | +113.3% |
| 2020 | -$0.15 | +34.8% |
| 2019 | -$0.23 | -1250.0% |
| 2018 | $0.02 | +109.5% |
| 2017 | -$0.21 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.04 | +108.0% | -50.0% |
| June 30, 2025 | $0.08 | +136.4% | +166.7% |
| March 31, 2025 | -$0.12 | +68.4% | +76.0% |
| September 30, 2024 | -$0.50 | -194.1% | -127.3% |
| June 30, 2024 | -$0.22 | +8.3% | +42.1% |
| March 31, 2024 | -$0.38 | -2.7% | -123.5% |
| September 30, 2023 | -$0.17 | +10.5% | +29.2% |
| June 30, 2023 | -$0.24 | -14.3% | +35.1% |
- OptimizeRx Corp showed an increase of +124.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2017–2025 period, OptimizeRx Corp’s diluted eps has grown by 228.6% (from $0.21 per share (loss) to $0.27 per share).
- The most recent figure is from OptimizeRx Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: